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Abstract
Cytotoxic T lymphocytes (CTLs) are important agents in the control of intracellular patho-
gens, which specifically recognize and kill infected cells. Recently developed experimental
methods allow the estimation of the CTL's efficacy in detecting and clearing infected host
cells. One method, the in vivo killing assay, utilizes the adoptive transfer of antigen display-
ing target cells into the bloodstream of mice. Surprisingly, killing efficacies measured by this
method are often much higher than estimates obtained by other methods based on, for in-
stance, the dynamics of escape mutations. In this study, we investigated what fraction of
this variation can be explained by differences in peptide loads employed in in vivo killing as-
says. We addressed this question in mice immunized with lymphocytic choriomeningitis
virus (LCMV). We conducted in vivo killing assays varying the loads of the immunodominant
epitope GP33 on target cells. Using a mathematical model, we determined the efficacy of ef-
fector and memory CTL, as well as CTL in chronically infected mice. We found that the kill-
ing efficacy is substantially reduced at lower peptide loads. For physiological peptide loads,
our analysis predicts more than a factor 10 lower CTL efficacies than at maximum peptide
loads. Assuming that the efficacy scales linearly with the frequency of CTL, a clear hierar-
chy emerges among the groups across all peptide antigen concentrations. The group of
mice with chronic LCMV infections shows a consistently higher killing efficacy per CTL than
the acutely infected mouse group, which in turn has a consistently larger efficacy than the
memory mouse group. We conclude that CTL killing efficacy dependence on surface epi-
tope frequencies can only partially explain the variation in in vivo killing efficacy estimates
across experimental methods and viral systems, which vary about four orders of magnitude.
In contrast, peptide load differences can explain at most two orders of magnitude.
Author Summary
The immune system reacts to the presence of a viral pathogen within the host by the elici-
tation of an immune response. This response is characterized by the activation and
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proliferation of specific cell types, which, for instance, produce neutralizing antibodies or
kill cells infected by the virus. Cytotoxic T lymphocytes (CTLs) function as an important
protecting element of the system by recognizing and clearing infected viral target cells.
Surprisingly, estimates of the killing efficacy of CTLs vary about four orders of magnitude
across experimental methods and viral systems. In some studies, CTL killing efficacies
were estimated by employing pre-treated cells that mimick virus infected cells. In general,
cells signal their infection by a pathogen to the immune system by presenting viral pep-
tides on their cellular surface. For the experimentally pretreated cells, these peptides were
artificially loaded onto the surface at very high densities. In this paper, we study to what
extent the variation in peptide densities can explain the variation found in killing efficacy
estimates across methods and viral systems. We found that peptide densities explain only
up to two orders of magnitude in killing efficacy variation. The remaining variation must
originate from other sources, which might be specific to the viral study system.
Introduction
Adaptive immune responses exert important selective pressures on viral infections through
various mechanisms, such as neutralization of virus particles by antibodies or killing virus-in-
fected cells by cytotoxic T lymphocytes (CTLs). Efforts to quantify the ability of CTLs to kill in-
fected host cells have yielded results with considerable variation [1, 2]. In fact, estimates of the
efficacy of CTLs at recognizing and clearing infected viral target cells in vivo vary by several or-
ders of magnitude between experimental designs and viral study systems [1, 3, 3–16].
In vivo CTL killing efficacy estimates exist for the following types of viral study systems:
HIV/SIV [4–11], lymphocytic choriomeningitis virus (LCMV) [3, 12–15], polyoma virus [16],
HTLV-1 [1], and bovine leukemia virus (BLV) [1]. The killing efficacy of CTLs in HIV [5, 6],
SIV [4, 9, 10], HTLV-1 [1], and bovine leukemia virus infection [1] yield distinct, relatively low
estimates. These estimates capture the rate at which a target cell is cleared by the total CTL re-
sponse, and range from 0.1d−1 to 10d−1 [1]. In contrast, polyoma virus and LCMV have been
shown to yield high killing efficacy estimates of 20−500d−1 for epitope-specific clones in either
acute or chronic infections [1, 3, 13–17]. Hence, compared to LCMV and polyoma virus,
HTLV-1 and BLV yield much lower estimates.
The variation in these estimates might be primarily due to the viral study systems. The ex-
perimental methods employed to obtain the estimates for HIV/SIV, HTLV-1 and BLV rely on
distinct approaches. HIV estimates are based on two approaches: the injection of CTL [5] and
on the observation of viral escape mutants [4, 6], with an almost hundredfold difference be-
tween some estimates [1]. In contrast, the HTLV-1 and BLV estimates are based on assessing
the decay rate of labeled cells, in a similar fashion as employed for LCMV and polyoma
virus [1].
Estimates for LCMV and polyoma virus rely on an experimental technique referred to as in
vivo killing assay. This technique involves the injection of target cells, loaded with viral peptides
on their surface, into the bloodstream of mice. The subsequent tracking of their disappearance
in relation to unpulsed control cells allows for the estimation of the effect of killing by CTLs. In
most of these assays, the number of viral peptides that each target cell displays is unnaturally
high, three orders of magnitude higher than on naturally infected cells (see Discussion).
In part, the discrepancy between the in vivo CTL efficacy estimates across experimental
methods and study systems is likely to arise from the unnaturally high peptide loads on target
cells in in vivo killing assays. The highest per CTL killing efficacies have been measured in
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LCMV in vivo killing assays with high peptide loads [14]. When reducing peptide loads to very
low levels which make target cells unrecognizable by CTL, we accordingly expect a decrease
per CTL killing efficacies to almost zero. Hence, peptide load variation could theoretically ex-
plain the entire variation in CTL killing efficacies.
In this study, we investigate to what extent CTL killing efficacies depend on peptide load on
target cells, and what proportion of the entire CTL efficacy variation can be explained by this
effect. To this end, we conducted CTL in vivo killing assays in mice acutely or chronically in-
fected with LCMV Docile. During chronic infections, CTLs are assumed to become dysfunc-
tional or exhausted, displaying poor effector function [18]. We estimated the killing efficacies
of effector, memory and chronic-infection CTLs for different peptide loads using mathematical
models that extend previous approaches [15]. The types of CTL were classified by the adminis-
tered dose of the LCMV Docile and the time after infection (see Materials and Methods).
We find that the per cell killing efficacy first increases with peptide loads, and saturates
above a peptide load of approximately 10−1 μg/ml. For physiologically reasonable peptide loads
however, which we estimate to lie around 10−3 μg/ml (see Discussion), the CTL efficacy is only
one order of magnitude lower than at saturation for all three CTL types. This leaves most of the
differences in in vivo CTL efficacy estimates unexplained.
We also found that individual CTL during chronic infections kill cells with physiological
peptide loads at a higher rate than effector or memory CTL. This result needs to be interpreted
in the context of whether exhausted CTLs display reduced killing efficacies [18]. As in studies
with high peptide loads [15], we found no evidence that CTL killing in chronic infections
is impaired.
Materials and Methods
Experiments
Ethical statement. Following the Felasa-recommmendation 2002 for laboratory animals,
C57BL/6 mice were kept under specific pathogen-free conditions. Animal experiments were
performed according to the guidelines of the animal experimentation law (SR 455.163; TVV)
of the Swiss Federal Government. The protocol was approved by the Cantonal Veterinary Of-
fice (animal experimentation number 127/2011).
Virus and viral peptides. The employed LCMV Docile was obtained by propagation on
MDCK cells at low multiplicity of infection. We employed methods described in [19] for the
quantification of infectious virus titres. Viral peptides used for pulsing on target cells (GP33-
41;KAVYNFATM) were purchased from NeoMPS (Strasbourg, France).
Cytotoxicity assay. LCMV Docile is known to cause acute or chronic infections depending
on the inoculum size of viral particles infecting the host [20]. We infected four groups of four
female C57BL/6 mice expressing the congenic marker Ly5.2 intravenously with LCMV-Docile
at distinct times before injecting target cells (Fig 1.). The first group (acute group) was infected
with an inoculum of 200 plaque forming units (pfu) eight days prior to transfer. Two further
groups (chronic and memory groups) were infected with 106 and 200 pfu, respectively, 42 days
prior to transfer. One group (naïve group) was used as negative control group. The terms used
to denote the treatment groups were chosen to describe the most prevalent CTL type found in
mice infected with a specific inoculum dose and at the time of the measurement. For each
mouse, the transferred target cell pool was comprised of 1.5 × 107 homozygous splenocytes
(and therefore Ly5.1+ Ly5.2-) and Ly5.1 heterozygous splenocytes (and therefore Ly5.1/Ly5.2
double positive).
With this design, it is possible to differentiate between cells originating from the recipient
mice, and the cells from the two transferred subpools (see Fig 2.). 5 × 106 cells in the first
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Ly5.1/Ly5.1 subpool were pulsed with 100 mg
ml
LCMV derived GP33 peptide for one hour at
37°C, and were stained with 2.5μMCFSE. Similarly, two further 5 × 106 cells of the same sub-
pool were pulsed with 101 mg
ml
GP33 (stained with 0.25μMCFSE) and 102 mg
ml
GP33 (not stained
with CFSE), respectively. The Ly5.1/Ly5.2 subpool was stained analogously to the first (2.5μM,
0.25μM and no CFSE), but pulsed with concentrations 103 mg
ml
, 104 mg
ml
and and no peptide (the
unpulsed subpopulation), respectively.
This design allows us to distinguish between all six subpopulations pulsed with different
peptide concentrations (including the unpulsed) by measuring the intensity of the CFSE dye as
well as the presence or absence of Ly5.1 and Ly5.2 congenic markers. Blood was harvested at
30, 60, 120, 240 min after transfer and analyzed for Ly5.2 and Ly5.1 expression, as well as
CFSE intensity.
Fig 1. Experimental design of the in vivo killing assay performed on four treatment groups of four mice.Mice in the control group (a) were not
challenged with LCMV and stayed naïve. Mice in the acute (b) and memory (d) groups were infected with 200 pfu, while the chronic group (c) received 1 × 106
pfu of LCMV Docile. After a delay of eight (acute group) and 42 days (chronic and memory groups) respectively, labelled target cells were injected
intravenously into all mice including the naïve group. The transferred cells consisted of subpopulations of cells pulsed with different peptide loads, including a
subpopulation of unpulsed cells. The subpopulations were pulsed with the indicated concentrations of GP33-epitope (5 × 106 cells each). At the indicated
time points, blood samples were taken and analysed for the proportions of the labelled cells by flow cytometry. Splenectomy was conducted on each mouse
4 hours after cell transfer and the splenocytes analysed for specific lysis of target cells and the proportions of epitope-specific CTLs. Note that in contrast to
[15], this design uses an additional treatment group—the memory group, a larger number of target cells is transferred, and the time between infection and cell
transfer is tuned to observe the desired effector, chronic and memory CTLs.
doi:10.1371/journal.pcbi.1004178.g001
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Four hours after the transfer, the mice were sacrificed and splenectomy conducted in order
to generate single cell suspensions. Splenocytes were analyzed for CD8 and GP33 tetramer
staining, as well as CFSE intensity and Ly5.1, Ly5.2 expression. All the relevant data obtained
from this experiment are given in S1 Data.
Flow cytometry. The antibodies for FACS were purchased from LucernaChem (Luzern,
Switzerland). For the generation of peptide/MHCI tetramers we followed [21]. Multiparameter
flow cytometric analysis was performed using a FACS LSRII flow cytometer (BD Biosciences,
Allschwil, Switzerland) with FACSDiva software. Analysis was performed using FlowJo soft-
ware (TreeStar, San Carlos, CA).
Statistics
We adopt a statistical framework which allows us to estimate the killing efficacy dependence
on the pulsing concentration of peptides on target cells separately for each of the treatment
groups (acute, chronic and memory groups), and to obtain estimates for the combined data set
of all groups.
Fig 2. FACS analysis of target cells before transfer can reliably differentiate target cell
subpopulations. To assess the reliability of our experimental design, we tested whether the six target cell
subpopulations pulsed at different peptide concentrations could be distinguished by their markers alone.
Before FACS analysis, equal numbers of the different target cell populations were mixed. The six target cell
subpopulations –no peptide in A), and pulsed with increasing GP33 peptide concentrations of 104 mg
ml
in B) to
1 mg
ml
in F)– employed in our study could reliably be differentiated according to their Ly5.1/Ly5.2 expression and
CFSE staining intensity. The percentages of detected target cells are given above the panels A) to F).
doi:10.1371/journal.pcbi.1004178.g002
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Following the notation established in [15], we index mice with i = 1, . . .,m, and label the
time points tl, where l = 1,   , L. Additionally, we have target cells pulsed at increasing concen-
tration λd, where d = 1, . . ., D. For each mouse i the experimental methods allow us to retrieve
the proportions of transferred target cells pulsed at concentrations λd, ~F ld ;iðtlÞ, as well as for
unpulsed cells, ~F u;iðtÞ in the blood at each time point. These data permit to estimate the proba-
bility of a target cell in mouse i pulsed with peptide concentration λd to be killed by the
GP33-specific CTL response until time tl:
p^i;ldðtlÞ ¼ 1
~F ld ;iðtlÞ
fd~F u;iðtlÞ
; ð1Þ
where as in [15], fd is used to correct for the different ratios that might arise in the inoculum.
To estimate fd, we calculated the ratios of cells pulsed with concentration λd and unpulsed cells
at each time point tl in naïve mice, and took the average of those values over all time points.
The key assumption for this procedure is that CTLs do not affect the proportions of transferred
target cells in naïve mice.
To estimate CTL efficacies and other quantities of interest in the killing assay data, a mathe-
matical model that predicts the fraction of killed target cells at time tl and peptide concentra-
tions λd, p(tl; λd) (see Results), is fitted to the data p^i;ldðtlÞ. For such a mathematical model two
assumptions need to be made for the killing. First, how peptide load λ affects the killing rate
constant k of CTLs has to be specified. Here, we assume a model with two parameters kmax and
l1
2
: kðkmax; l12; lÞ (see Results for interpretation of these parameters).
Second, a further assumption is required as to how the total killing efficacy is affected by the
presence of other CTLs within the same compartment. Here, a general model might describe
the net effect of the overall epitope-specific CTL frequency g(C), where C denotes the propor-
tion of CTLs specific to the pulsed epitope among all splenocytes. The total killing—usually
denoted by f(k, C) [3]— is captured by a mathematical expression incorporating both killing
dependence on pulsing load and CTL saturation: f kðkmax; l12; ldÞ; gðCiÞ
 
.
Fitting is realized by employing a least square algorithm on the arcsin-square-root trans-
formed data and probabilities [22]. The expected killing probabilities depend upon the model
of choice, as shown in (3). Hence, the algorithm minimizes:
XD
d¼1
X
i2IT
XL
l¼1
arcsin
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p^ tl; f k kmax; l1
2
; ld
 
; gðCiÞ
  s !
arcsin
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pi;ldðtlÞ
q  !2
; ð2Þ
where IT denotes the index set of mice over which the minimization is carried out. These data
can stem from the mice within the same treatment group, or from a combined data set from all
treatment groups. The parameters in the killing model f(k, C), such as kmax and l1
2
, are estimat-
ed by incorporating the model into Eq (3), and ﬁtting it to the observed fraction of pulsed tar-
get cells (1).
We used the R language for statistical computing [23] for the mathematical analysis per-
formed on the data.
Results
(a) CD8+ T cell responses
The acute, chronic and memory groups differed in the overall frequencies of CD8+ T cells in
the spleen four hours after the transfer of target cells (Fig 3A.). We performed two-tailed t-tests
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on the log-transformed frequencies among all groups to assess the inter-group differences. Ap-
plying the Holm-Bonferroni correction, we found that only half of the group pairs differed sig-
nificantly. Acute and memory groups (p = 0.31), as well as the naïve and memory groups
(p = 0.03) did not differ significantly in their total CD8+ T cell frequency. We also measured
the GP33-specific CD8+ T cells in the spleen (Fig 3B.). All groups differed significantly, with
the exception of acute and memory groups (p = 0.26). For both, the overall frequency of CD8+
T cells and the frequency of GP33-specific CD8+ T cells in the spleen, the acute and memory
groups attained the highest values, whereas the number of cells in the chronically infected
groups was lower compared to the acute and memory group but above the naïve group.
(b) Target cell frequencies in blood and spleen
The level of pulsing of target cells heavily influenced their clearance by GP33-specific CD8+ T
cells. The more peptides were loaded onto target cells before transfer, the faster the target cells
disappeared relative to the total number of target cells. Fig 4. shows that in the naïve group rela-
tive target cell frequencies stayed approximately constant over the whole time course of the ob-
servation. In contrast, target cell frequencies for the other three groups show a significant
reduction of most pulsed target cells when compared to unpulsed cells. Target cells which were
pulsed at concentrations of 104 mg
ml
of GP33 epitope increase in frequency in a similar fashion
as the unpulsed cells, indicating that these pulsed cells are killed at very low rates.
(c) Estimation of killing efficacy dependence on pulsing concentration
The measurement of the target cell frequencies relative to control cells contains information
about how fast these target cells are cleared by CD8+ T cells. To extract this information, math-
ematical modeling is required to synthesize the migration of cells between the blood and
Fig 3. Frequency of CD8+ T cells in the spleen 4 hours after transfer of the target cells. Following the experimental design, splenectomies were
conducted on the mice of all treatment groups. Panel A) shows the total frequencies of CD8+ T cells and B) the frequencies of the GP33-specific CD8+ T cells
among splenocytes in naïve (unfilled), acute (light grey), chronic (dark grey) and memory (black) treatment groups found in the spleen 4 hours after the
transfer of target cells. The black connecting lines show significant deviations in the CD8+ T cell frequencies between groups, and are given with the
associated p-values.
doi:10.1371/journal.pcbi.1004178.g003
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secondary lymphatic tissues with the dynamics of killing by CTL. The mathematical model we
used extends the previous model [15] by explicitly describing the dependence of the killing rate
on the peptide load on the target cells.
To predict the proportions of killed target cells with a mathematical model, more detailed
information is required as to how the target cells circulate in the blood and in which compart-
ments they are killed. In previous work [15], we conducted experiments in naïve mice to deter-
mine at what rates target cells migrate to different compartments, such as the spleen, lung, liver
and blood of mice. In these experiments, the total fraction of transferred target cells had been
measured in all compartments over time. In a first step, we had observed that the target cells
are likely to exclusively home to the spleen. For this reason, we assume that all target cells are
killed in the spleen only. In a second step, we had calculated the net flux rate of target cells into
the spleen, μ(t).
Fig 4. Relative frequency of target cells in the blood over time for the different mouse groups. The frequencies are given relative to the total target cell
pool measured at 30, 60, 120 and 240 minutes after transfer. A) The frequencies of the target cells in the naive, B) acute, C) chronic and D) memory groups
are shown for each individual mouse. The group means for each measurement are connected by lines specific to the pulsing concentration. The frequencies
of the target cells found in the spleen after 4h are shown separately next to the dashed black line.
doi:10.1371/journal.pcbi.1004178.g004
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In the present study, we use the the estimate of μ(t) from [15]. The calculation of μ(t) is
based on the existence of two compartments, a risk compartment –the spleen– where target
cells can be cleared, and a non-risk compartment where they are not actively cleared. The net
flux μ(t) between these two compartments constitutes a simplification to fluxes employed for
inference in earlier models [3, 13] and should not be equated to such fluxes.
How efficiently the target cells are killed in the spleen by CD8+ T cells is determined by how
abundant GP33-specific CD8+ T cells are in the spleen and the peptide load λ. These effects are
mathematically captured in an expression for the total killing rate of the target cell population,
f(k, λ, C). In this expression, k denotes the killing rate constant that describes the functional re-
lationship between killing rate, CTL abundance C, and peptide load. The form of f(k, λ, C) will
be specified below. We denote the proportion of killed target cells pulsed at concentration λ at
time t by p^i;lðtÞ.
With the previously determined net flux rate μ(t) of cells between spleen and blood, and the
total killing rate f(k, λ, C) we can derive the probability of a target cell to be killed by CTL’s
until time t:
pðt; k; l;CÞ ¼(
1 ðeðR t0mðsÞdsÞ þ R t
0
eð
R u
0
mðsÞdsÞmðuÞeðf ðk;l;CÞðtuÞÞduÞ if t  t0
pðt0; k; l;CÞ þ
R t0
0
eð
R u
0
mðsÞdsÞmðuÞeðf ðk;l;CÞðt0uÞÞdu R tt0 eðR ut0 mðsÞf ðk;l;CÞdsÞf ðk; l;CÞdu if t > t0;
ð3Þ
where, t0 denotes the time at which the netflux rate μ(t) becomes negative [15]. The deriva-
tion of this expression is based on the assumption that the target cells’ probability to be killed
in the spleen depends on the target cells’ transition rate through the spleen, which roughly cor-
responds to μ(t). The dynamics of target cell circulation changes with the sign of μ(t): If μ(t) is
positive, the probability of a target cell to be located in the spleen, and hence to be killed by
CD8+ T cells, increases. If μ(t) is negative, this risk decreases. A detailed derivation of Eq (3) is
provided in the supplementary information of [15].
(c1) Killing efficacy dependence model under mass-action kinetics
To fit Eq (3) to the observed frequencies of pulsed cells, p^i;lðtÞ, we need to specify how the kill-
ing rate f(k, λ, C) depends on the level of GP33-specific CD8+ T cells in the spleen and the pep-
tide load λ. Here, we assume this dependence to be given by:
f ðk; l;CÞ ¼ k kmax; l1
2
; l
 
C ¼ kmaxl
l1
2
þ lC; ð4Þ
This expression assumes that the killing rate linearly increases with the frequency of GP33-spe-
ciﬁc CD8+ T cells, known as the mass-action killing assumption [24]. The parameters kmax and
l1
2
characterize how the killing rate constant depends on the peptide load on the target cells
(Fig 5.). kmax is the maximal killing efﬁcacy and l1
2
accounts for the sensitivity of CTL’s to the
frequency of presented epitopes on the target cell surface.
This model disentangles two aspects of the per cell killing efficacy k: the sensitivity parame-
ter l1
2
determines the peptide loads required for a CTL to kill, while the parameter kmax de-
scribes the maximal killing capacity that can be reached per cell. In principle, it is possible that
the hierarchy of killing abilities between CTL population depends on the peptide load on the
target cells. For example, the CTL population described by the blue curve in Fig 5. is less sensi-
tive to the peptide concentration on target cells than the other CTL populations and is there-
fore less efficacious, except for very high peptide loads.
CTL Killing Efficacy Dependence on Peptide-MHC Complex Densities
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We fitted function (3) assuming the killing efficacy dependence model defined in Eq (4) to
the data. We found that the two parameters characterizing the killing rate in the mass-action
killing model differed significantly between the acute, memory and chronic groups (F-test,
p = 2  10−33). For this reason, we analyzed the three groups separately from this
point onwards.
The maximum likelihood estimates for the maximum killing parameter kmax and the sensi-
tivity l1
2
, and their confidence intervals are listed in Table 1 and visualized in Fig 6. The estimates
for kmax and l1
2
show a marked dominance of the maximum killing rate for chronically infected
mice. The estimated maximal killing efficacy for the acutely infected mice (kmax = 1.71 min
−1) is
around three times smaller than the corresponding efficacy for chronically infected mice (kmax
= 4.88 min−1), and about 1.4 times larger than the memory group mice (kmax = 1.19 min
−1).
Fig 5. Curves of the killing efficacy model for different values of parameter pairs. The killing efficacy
model kðkmax; l12; lÞ accounts for the varying efficacy of individual CD8
+ T cells at killing target cells (k) at
different peptide pulsing concentrations λ. The parameter kmax is the maximal killing rate of CD8
+ T cells,
where higher peptide concentrations λ do not increase CD8+ T cell killing. The parameter l1
2
describes at
which peptide load killing is half-maximal. The lower this value, the more sensitive the CD8+ T cell is to
peptide: a less sensitive CD8+ T cell would kill at lower rates at the same peptide concentrations. With this
model, the comparison of two CTL types determined by distinct parameter pairs can lead to counter-intuitive
results. For example, CD8+ T cells with low sensitivity but high maximal killing efficacy (blue line: kmax = 1.9,
l1
2
¼ 1) will be less efficient than more sensitive CD8+ T cells (red line: kmax = 1 and l1
2
¼ 3 and green line:
kmax = 1.5 and l1
2
¼ 1:8) over a wide range of pulsed tetramer concentrations.
doi:10.1371/journal.pcbi.1004178.g005
Table 1. Estimates of kmax and l1
2
for different treatment groups. The confidence intervals were calculated
with 1000 bootstrap replicates and the percentile method.
treatment group kmax[min−1] l1
2
½mg
ml

(a) acute 1.71 (1.27, 2.41) 10−2.24 (10−2.42, 10−2.05)
(b) chronic 4.88 (4.33, 5.51) 10−2.14 (10−2.28, 10−2.01)
(c) memory 1.19 (0.96, 1.48) 10−2.13 (10−2.26, 10−1.99)
doi:10.1371/journal.pcbi.1004178.t001
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We calculated the associated minimal half-lifes by factoring in the proportion of GP33-
specific splenocytes. The half-lifes calculated are 10.64 min, (95% CI: (6.65, 14.62)) for the
acute, 22.58 min, (95% CI: (18.82, 26.33)) for the chronic and 19.09 min, (95% CI: (16.11,
22.08)) for the memory groups.
The decimal logarithm of the epitope recognition sensitivity was estimated to be highest for
the acute group (102:24 mg
ml
), and almost identical for the chronic and the memory groups
(102:14 mg
ml
, 102:13 mg
ml
(Table 1)).
Fig 7. shows the fits of function (3) incorporating (4) for each group. The five curves shown
for each group correspond to five peptide loads inserted into function (3), which is parame-
trized with the estimates in Table 1. Note that to generate all curves within a group only two pa-
rameter values are required. The simple model (4) is capable to successfully capture the most
pronounced features of the data remarkably well.
By using bootstrapping, we were able to calculate 95% confidence bands for the per-cell effi-
cacy profile across all peptide loads (Fig 8.). The CTL’s in the chronically infected mice show
larger killing efficacies than the other groups. The acutely infected group reveals significantly
larger killing efficacies for concentrations up to 101 mg
ml
compared to mice from the memory
group. Thus, although hierachies that change with peptide loads would be theoretically possible
in our model, as shown in Fig 5., we infer a clear and unchanging hierarchy across
peptide loads.
Fig 6. Likelihood landscapes from independent bootstrap procedures on the acute, chronic and
memory treatment groups. Per group, 1000 bootstrap runs were repeated. A correlation between the
estimates for kmax and l1
2
is visible for all three groups.
doi:10.1371/journal.pcbi.1004178.g006
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(c2) Estimates under saturation of CTL responses
According to the mass-action assumption the killing rate increases linearly with the frequency
of CTL. At very high CTL frequencies, however, the killing rate will stop to increase and satu-
rate. Recent studies based on cellular automata predict a threshold in CTL frequencies of 0.03,
above which saturation effects in CTLs should not be neglected [25]. Below this threshold,
mass action dynamics is an appropriate approximation [26]. In our data, the threshold is ex-
ceeded in the acute group (hCai = 0.042) and slightly in the memory group (hCmi = 0.031), but
not the chronic group (hCpi = 0.006).
Fig 8. Estimated dependence of killing efficacies on pulsed peptide concentrations λwith 95%
confidence intervals from bootstrap replicates. The values for the chronic treatment group (green) are
clearly larger than values for the acute (red) and memory (blue) groups. The confidence intervals were
calculated by determining the 2.5% and 97.5% percentiles of the distribution of kðkmax; l12; lÞ values for all
bootstrapped parameter pairs ðkmax; l12Þ (where 1000 parameter pairs were evaluated) at each concentration λ.
doi:10.1371/journal.pcbi.1004178.g008
Fig 7. Fitted curves of Eq (3) assumingmass-action kinetics on estimated fractions of killed target cells in all mouse groups. The curves depend on
the killing efficacy model kðkmax; l12; lÞ for distinct estimated group-specific values of parameter pairs (kmax, l12) for A) the acute, B) the chronic and C) the
memory groups. The dots are the averages of the fraction of killed target cells of all mice in a treatment group. The estimated values are given in Table 1. The
five different lines for each group were calculated with Eq (3) using the group specific parameter pairs, as well as the pulsed peptide concentrations λ.
doi:10.1371/journal.pcbi.1004178.g007
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For this reason, we relaxed the mass-action assumption and assumed that the killing rate
saturates with increasing CTL frequencies. Saturation in CTL frequencies implies that the kill-
ing efficacy per CTL approaches an upper limit with increasing CTL numbers. The individual
CTL killing efficacy is thus impaired by the presence of other CTLs in the same compartment.
If we incorporate the saturation in CTL frequencies into our model for killing, we obtain the
following killing rate:
f ðkðkmax;j; l12;j; lÞ;C12;jÞ ¼
kmax;jl
l1
2;j
þ l 
Cj
C1
2;j
þ Cj ð5Þ
Here j 2 {a, p,m} denotes the acute, chronic and memory groups, respectively. C1
2;j
is the CTL
frequency, at which the saturation effects in Cj are half-maximal, and is sometimes confusingly
referred to as the saturation threshold.
With the adoption of a saturation model, the meaning of the killing efficacy k, and with it of
the parameter kmax changes. In the mass action model, k is the per cell killing efficacy induced
by a peptide load λ. Therefore, kmax signifies the maximum per cell killing efficacy that can be
attained by a CTL. However, in the saturation model, k and kmax have a less intuitive meaning.
Here, k is the actual killing rate exerted by all peptide-specific cells at a particular peptide load
λ accounting for CTL saturation effects. Hence, in the saturation model, kmax captures the max-
imum killing rate that can be reached by the entire CTL population specific to a
particular peptide.
While it is conceivable that the half-maximum CTL frequencies C1
2;j
differ by group, we do
not have the resolution in our experimental data to determine these parameters for each group
individually. This is due to the very low variation of CTL frequencies in different mice within
the groups. We therefore defined killing model variants of increasing complexity, starting with
a variant in which all parameters are equal between groups, to variants in which increasing
number of parameters differ. We refer to these model variants as Model A, B, C, and D. The
choice of these models was biologically motivated, and represents a subset of all theoretically
conceivable combinations of inequalities between group parameters.
We performed F-tests between these four models. In model A we assume all maximum kill-
ing efficacies within treatment groups to be equal kmax,a = kmax,p = kmax,m, all sensitivities on
concentration between groups to be equal, l1
2;a
¼ l1
2;p
¼ l1
2;m
, as well as the saturation levels for
CTLs, C1
2;a
¼ C1
2;p
¼ C1
2;m
. Model B is given by the assumption that sensitivities between the
treatment groups are independent or not necessarily equal, l1
2;a
6¼ l1
2;p
6¼ l1
2;m
. Model C is given
by assuming an difference between memory cell CTL saturation levels and effector cell satura-
tion levels: C1
2;a
¼ C1
2;p
6¼ C1
2;m
. Model D adds further complexity to model C by relaxing the as-
sumption of equal maximum killing efficacies: kmax,a 6¼ kmax,p 6¼ kmax,m.
We found that model B provides a significantly better fit than model A (p = 3.53  10−9, by
F-test). Model C provides a significant improvement of a fit over model B (p = 2.21  10−5). In-
triguingly, model C (six parameters) does also lead to a better fit of the data than the combina-
tion of all group-wise fits of the mass-action kinetics model with killing efficacy dependence on
pulsing concentrations (also six parameters, identical data). The mass action model leads to a
residual sum of squares (RSS) of 3.43, whereas model C leads to an RSS of 3.33. Also when
comparing these two models by the Akaike Information Criterion (AIC), model C is associated
with a smaller information loss (AIC: 301) than the mass-action model (AIC: 308.14). Here,
AIC was calculated as AIC = 2k + n log(RSS) [27, 28], where the number of parameters in the
model is k = 6 and the number of observations is n = 240, see S1 Text. The fit of model C to the
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data is shown in S1 Fig. Lastly, model D does not significantly improve the fit compared to
model C (p = 0.323).
In addition to models A, B and D, we tested several other alternatives to model C, and
found that model C is statistically the best supported model (see S1 Text and S2 Fig).
The fact that model C comes out as the best model in our model selection scheme is consis-
tent with biological observations and previous quantitative analyses. Studies which employed
mass-action kinetics for low effector-target cell ratios, found no significant differences between
the killing efficacy of CTLs in acute and chronic infections [15], as well as between effector and
memory CTL [3, 29]. This is in line with the assumption of model C that the maximum killing
efficacies of CTLs in all mice groups are equal kmax,a = kmax,p = kmax,m. The model assumption
of unequal half-maximum CTL frequencies differ between memory and effector CTL is sup-
ported by the observation that memory CTL bind to target cells longer until they kill due to
lower perforin and granzyme levels [30].
We fitted function (3) under model C to the combined data of all treatment groups. Confi-
dence intervals were obtained by bootstrapping. The estimated values of the model parameters
are shown in Table 2. Estimated maximum killing efficacies are smaller compared to the mass-
action kinetics estimates, because of a different gauging under the new saturation assumption.
The estimates for the peptide load sensitivities are very similar to those in mass-action esti-
mates (shown in Table 1). For the saturation threshold in C1
2;effector
, we obtain values around
0.015. This estimate is very similar to one obtained by different methods (see S1 Text). The sat-
uration threshold estimate for memory CTL is substantially higher than for CTL in acute and
chronic infections.
Discussion
In this study, we have estimated CTL-mediated killing efficacies using in vivo killing assays
across a wide range of peptide loads. Assuming mass-action kinetics, a clear hierarchy emerged
between acute, chronic and memory responses. The chronic group showed a larger killing effi-
cacy per CTL than the acute group, which in turn was more effective than the memory group
across the entire range of peptide loads. This clearly shows, consistent with previous studies
[15, 20], that CTL during chronic infections are not impaired in their ability to kill. Neither do
these cells require more peptide on their targets to kill (l1
2
), nor do they have a lower killing effi-
cacy for very large peptide loads.
In contrast to our previous work [15], the estimates of the maximal per CTL killing effica-
cies were around one order of magnitude smaller for the acutely infected mice. This mismatch
Table 2. Estimates of kmax and l1
2
;a, l1
2
;p, l1
2
;m, as well asC1
2
;eff andC1
2
;mem under model C for all treatment
groups combined. The confidence intervals were calculated with 1000 bootstrap replicates and the
percentile method.
parameter value
(a) kmax[min
−1] 0.095 (0.055, 0.138)
(b) l1
2;acute
½mg
ml
 10−2.23 (10−2.44, 10−2.10)
(c) l1
2;chronic
½mg
ml
 10−2.16 (10−2.29, 10−1.99)
(d) l1
2;memory
½mg
ml
 10−2.15 (10−2.28, 10−1.93)
(e) C1
2;effector
0.013 (0.004, 0.023)
(f) C1
2;memory
0.051 (0.007, 0.088)
doi:10.1371/journal.pcbi.1004178.t002
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for the acute group is likely due to CTL frequency saturation effects. Saturation effects are likely
to play a smaller role in [15], where due to later cell transfer times (15 days after infection) the
average GP33-specific CTL frequency is about 0.01. In this study, the average GP33-specific
CTL frequency in acutely infected mice was 0.042 (8 days after infection). As the frequencies of
GP33-specific CTL increase, killing efficacies will inevitably enter a saturation regime. In the
saturation regime, a further increase in CTL does not lead to more total killing, violating a core
assumption of the mass-action model. Erroneously adopting the mass-action assumption
under saturation will therefore lead to an underestimate of the per CTL killing efficacy.
In contrast, GP33-specific CTL frequencies for chronically infected mice in the experiments
presented in [15] were very similar to those in this study, and no inconsistencies between kill-
ing efficacy estimates arise.
To account for possible saturation effects in CTL numbers we also investigated mathemati-
cal models accounting for the saturation in killing rates for high CTL levels. Such saturating ef-
fects arise when the duration of killing is the limiting factor in the dynamics [31]. By a variety
of methods we estimate that GP33-specific CTL need to exceed a frequency of 1% among sple-
nocytes for saturation in acute and chronic infection. This estimate is about two to three times
lower than that obtained from cellular automata models [25].
The results for the estimated recognition sensitivities between groups are almost identical
between mass-action kinetics and CTL saturation model fits. Irrespective of the mass-action as-
sumption, we did not find significant differences in the recognition sensitivities between re-
sponses. These estimates are of the same order of magnitude as comparable estimates found
for chronic infections of polyoma virus, but differ for acute infections [16].
This study relies on estimates of the net unpulsed target cell migration into the spleen μ(t)
and target cell data from the blood obtained in previous work [15]. Hence, uncertainties re-
garding the migration of target cells into the spleen that are associated with the experimental
approach will inevitably be inherited by our killing efficacy estimates.
There exist other models for CTL killing, such as the refractory model, epitope decay and
CTL exhaustion models [13] or a recently investigated double saturation model [32], that
could have been used to fit the data. In this study, we limited the analysis to the standard mass-
action kinetics and CTL saturation models. The refractory and exhaustion models were found
to contradict biological observations in [13]. The CTL epitope decay model accounts for the
observation that peptide-MHC complexes have lifetimes on the order of hours [33], and could
be lost over the course of our experimental study. However, in our previous study, this model
did not provide significantly better fits to standard models [15]. Furthermore, the model could
not provide additional information as to the relative strengths of the responses in the different
treatment groups. The double saturation model—which accounts for saturation in both target
as well as CTL numbers– could capture the functional response of the killing in a variety of
conditions simulated in a computer model of lymphoid tissue. However, the relatively low vari-
ance in the target cell numbers in the spleen (0.08−0.12 probability for a target cell to be in the
spleen [15]) as well as the low variance of CTL frequencies do not permit to resolve the quanti-
tative details of saturation in our data.
The main motivation for estimating CTL killing efficacies for lower peptide loads in the
present study were the discrepancies between killing estimates in vivo across a broad range of
study systems [1, 3–16]. However, there are also inconsistencies across in vivo and in vitro
studies. It is unresolved if CTL are equally able to kill during chronic and acute LCMV infec-
tion. Some studies report cytolytic impairment of CTLs in chronic infections [34–36], while
others find unchanged cytotoxic potential in chronic infection [20]. These inconsistencies were
thought to arise because the study systems employ either different peptide-MHC densities or
different cells [20]. Our study shows that lower peptide-MHC densities by themselves cannot
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explain the impaired killing ability that some studies found: the killing ability during chronic
LCMV infection is at least as strong as during acute infection across all peptide loads we tested
in our study.
Our estimates do not completely resolve why there are discrepancies of many orders of mag-
nitude in CTL killing efficacy estimates between HIV, SIV, BLV, HTLV-1 on one hand, and
LCMV and polyoma virus on the other. The peptide loads on naturally infected cells corre-
spond to a peptide pulse of approximately 103 mg
ml
. This number is estimated from a comparison
of the T-cell stimulation by LCMV-infected or peptide-pulsed macrophages. An identical acti-
vation level of macrophages is attained for T-cells pulsed at 109M  103 mg
ml
. The killing effica-
cies obtained in in vivo killing assays with for the commonly applied large pulses of 1 mg
ml
and the
physiologically more realistic pulse of 103 mg
ml
differ by a factor 10. Thus, lower peptide loads ex-
plain only up to two orders of magnitude difference in CTL killing rates, and alternative expla-
nations for the remaining large discrepancies need to be sought.
The discrepancies between the estimated killing efficacies could be due to specific differ-
ences between the host species and the viruses. For instance, differences in the distribution of
MHCmolecules on target cells between mice and primates could have important effects. Other
important host features, such as size, might affect CTL killing. Virus features are also expected
to impact CTL killing efficacy. For example, viral protein expression in infected cells might
vary substantially between different viruses and the infected cell type. Additionally, epitopes
from different pathogens might elicit differently strong immune responses, which could con-
tribute to CTL killing efficacy variation.
Other studies have previously shown that the peptide concentration employed for target cell
pulsing can affect the killing efficacies of CTLs in polyoma virus (PyV) [16, 37]. As in our own
study, killing efficacies declined with decreasing pulsing concentrations, indicating that the
CTL’s ability to recognize and kill infected target cells depends on the number of peptide/MHC
molecules presented on the target cell surface. In contrast to our results, fits of mass-action
models do not show a clear hierarchy of killing efficacies between CTLs in acute and chronic
infections. Rather, the hierarchy of killing abilities of CTLs in acute and chronic infections is
reversed when pulsing concentrations are varied. Although this study differs in scope and in
the viral system from the study of [16], it can be regarded as an extension of it. Here, we have
additionally investigated saturation models by employing statistical methods established in re-
cent studies (arcsin transformations for adequate error minimization in frequency data [13],
estimation of net flux rates of target cells into spleen [15]).
Compared to the primary response after encounter of a pathogen, memory T cells confer a
faster and stronger immune response to the host upon re-encounter, granting increased protec-
tion [38]. As in previous studies [13], we found that memory CTL do not kill at higher rates
than CTL in acute and chronic infections, particularly at lower peptide loads. We therefore
have no evidence for an increased sensitivity of memory CTL compared to acute or chronic
CTL, as has been suggested [39]. The increased level of viral control that is observed upon re-
exposure is better explained by higher initial number or a higher proliferative capacity of mem-
ory CTL as compared to naïve CTL.
Supporting Information
S1 Text. Supporting information text. The Supporting Information Text S1 contains an alter-
native estimation method for the saturation threshold C 1
2;effector
, an explanation of how the
model selection of model C was carried out and a mathematical derivation for the formula
used for the Akaike Information Criterion calculations in the manuscript.
(PDF)
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S1 Fig. Fitted curves of Eq (3) assuming saturation in CTL killing (model C) on estimated
fractions of killed target cells in all mouse groups. The curves were obtained by using the es-
timates for the parameters in model C (see Table 2) to plot (3). The panels show the fits to
(left) the acute, (middle) the chronic and (right) the memory groups. The dots are the averages
of the fraction of killed target cells of all mice in a treatment group.
(TIF)
S2 Fig. Selection of model C. Starting from very restrictive assumptions for a model of CTL
behavior across treatment groups (top circle), additional relaxing assumptions lead to models
with increasing numbers of parameters (circles below, connected by arrows). Whether models
derived from more restrictive, nested models provide a significantly better fit to the data is as-
sessed by F-tests. The p-values associated with each relaxed model assumption (arrows) are the
outcomes of F-tests between the two models that have been fitted to the data set that includes
mice from all treatment groups. The AIC values for each model are given within each model-
specifying circle. Model C is selected as the model which increases the quality of the fit most
significantly, but does not allow a further relaxation of assumptions.
(TIF)
S1 Data. Experimental data. The data used for the analysis is represented as a table. The first
column is the name of the sample, the columns denoted with "unpulsed" or "_gp33" are the
relative proportions of the transferred cell subpopulations, pulsed with the corresponding con-
centrations. "location" denotes whether the data were taken from the blood (1) or from spleen
(2). "Time" is the time after transfer at which the samples were taken, in minutes. "mouse.nr" is
the number of the mouse examined, where mouse numbers 1-4 belong to the naive, 5-8 to the
acute, 9-12 to the chronic and 13-16 to the memory groups. "CD8" is the total frequency and
"CD.GP33" is the frequency of GP33-specific CD8+ T cells among splenocytes. The column
names "pcGP33.killed" denote the percentage of cells killed in the subpopulations of the corre-
sponding pulsing concentrations. The rest of the columns were not used for analysis.
(CSV)
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